{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:42:17Z","timestamp":1793313737404,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA264078"],"award-info":[{"award-number":["CA264078"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA245499"],"award-info":[{"award-number":["CA245499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA129243"],"award-info":[{"award-number":["CA129243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA300788"],"award-info":[{"award-number":["CA300788"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.annonc.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:12:04Z","timestamp":1750101124000},"page":"1142-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases"],"prefix":"10.1016","volume":"36","author":[{"given":"J.A.","family":"Wilcox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-761X","authenticated-orcid":false,"given":"M.Y.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tischfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6002-7278","authenticated-orcid":false,"given":"J.S.Y.","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6971-1408","authenticated-orcid":false,"given":"D.","family":"Nemirovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-6425","authenticated-orcid":false,"given":"J.S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Riely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-1248","authenticated-orcid":false,"given":"A.A.","family":"Boire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.annonc.2025.06.001_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","article-title":"Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies","volume":"18","author":"Popat","year":"2023","journal-title":"Targ Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2025.06.001_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2018.00088","article-title":"Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment","volume":"8","author":"Remon","year":"2018","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.06.001_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.001_bib7","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2214\/AJR.21.25787","article-title":"Development of brain metastases in patients with non\u2013small cell lung cancer and no brain metastases at initial staging evaluation: cumulative incidence and risk factor analysis","volume":"217","author":"Kim","year":"2021","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.annonc.2025.06.001_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.912505","article-title":"Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.06.001_bib9","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.06.001_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2018.11.022","article-title":"Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer","volume":"127","author":"Wu","year":"2019","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2025.06.001_bib11","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib12","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1038\/s41467-023-40793-x","article-title":"Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis","volume":"14","author":"Skakodub","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.001_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","article-title":"Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma","volume":"52","author":"Shih","year":"2020","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.annonc.2025.06.001_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oncolo\/oyac094","article-title":"Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases","volume":"27","author":"Huang","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.annonc.2025.06.001_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1535-7163.MCT-20-0579","article-title":"Salting the soil: targeting the microenvironment of brain metastases","volume":"20","author":"Srinivasan","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"10.1016\/j.annonc.2025.06.001_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.06.001_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s13238-021-00855-6","article-title":"Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.001_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jamia\/ocw020","article-title":"Automated eligibility screening and monitoring for genotype-driven precision oncology trials","volume":"23","author":"Eubank","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.001_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.001_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2025.06.001_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.06.001_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epithelial growth factor receptor 2 (ERBB2) amplification status","volume":"19","author":"Ross","year":"2017","journal-title":"J Mol Diagn"},{"issue":"8","key":"10.1016\/j.annonc.2025.06.001_bib26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41588-018-0165-1","article-title":"Genome doubling shapes the evolution and prognosis of advanced cancers","volume":"50","author":"Bielski","year":"2018","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.001_bib27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.annonc.2025.06.001_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"283","key":"10.1016\/j.annonc.2025.06.001_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1408","article-title":"Clonal status of actionable driver events and the timing of mutational processes in cancer evolution","volume":"7","author":"McGranahan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.annonc.2025.06.001_bib30","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.annonc.2025.06.001_bib31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"issue":"10","key":"10.1016\/j.annonc.2025.06.001_bib32","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7878","key":"10.1016\/j.annonc.2025.06.001_bib33","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2025.06.001_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jtho.2022.10.004","article-title":"UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in First-LiNe setting (UNICORN)","volume":"18","author":"Bar","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.06.001_bib35","article-title":"Osimertinib in NSCLC with atypical EGFR-activating mutations: a retrospective multicenter study","volume":"4","author":"Ji","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.annonc.2025.06.001_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non\u2013small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"Watanabe","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.06.001_bib37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.06.001_bib38","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-022-09245-5","article-title":"Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters","volume":"22","author":"Zeng","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib40","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/s41467-022-34889-z","article-title":"Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer","volume":"13","author":"Adua","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.001_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-21-0910","article-title":"Targeting S100A9\u2013ALDH1A1\u2013retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer","volume":"12","author":"Biswas","year":"2022","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2025.06.001_bib42","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd.2017.07.57","article-title":"Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer","volume":"9","author":"Li","year":"2017","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib44","article-title":"Genomic landscape and actionable mutations of brain metastases derived from non\u2013small cell lung cancer: a systematic review","volume":"5","author":"Andrews","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"20","key":"10.1016\/j.annonc.2025.06.001_bib45","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.32372","article-title":"Genes associated with increased brain metastasis risk in non\u2013small cell lung cancer: comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)","volume":"125","author":"Wang","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2025.06.001_bib46","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1158\/1541-7786.MCR-20-0753","article-title":"Gene body methylation of the lymphocyte-specific gene CARD11 results in its overexpression and regulates cancer mTOR signaling","volume":"19","author":"McGuire","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.001_bib48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ccell.2023.03.018","article-title":"Genomic mapping of metastatic organotropism in lung adenocarcinoma","volume":"41","author":"Lengel","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41591-024-03286-y","article-title":"Prediction of brain metastasis development with DNA methylation signatures","volume":"31","author":"Zuccato","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13046-024-03220-7","article-title":"MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC","volume":"43","author":"Liu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2025.06.001_bib51","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jtho.2023.05.007","article-title":"Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification","volume":"18","author":"Elkrief","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.06.001_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00241","article-title":"Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification","author":"Elkrief","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2025.06.001_bib53","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1158\/0008-5472.CAN-15-0562","article-title":"Metastatic competence can emerge with selection of preexisting oncogenic alleles without a need of new mutations","volume":"75","author":"Jacob","year":"2015","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.001_bib54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41556-024-01409-8","article-title":"Cell-intrinsic and microenvironmental determinants of metastatic colonization","volume":"26","author":"Lambert","year":"2024","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.annonc.2025.06.001_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2020.03.014","article-title":"An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non\u2013small-cell lung cancer","volume":"132","author":"Tsakonas","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.001_bib56","article-title":"Gene expression profiling of breast cancer brain metastasis","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.001_bib57","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a037242","article-title":"Brain metastasis organotropism","volume":"10","author":"Yuzhalin","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.06.001_bib58","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"issue":"6501","key":"10.1016\/j.annonc.2025.06.001_bib59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.annonc.2025.06.001_bib60","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2025.06.001_bib61","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor\u2013mutated advanced non\u2013small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.06.001_bib62","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.06.001_bib63","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/JCO.2024.42.16_suppl.8517","article-title":"A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease","volume":"42","author":"Yu","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425007823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425007823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:21:57Z","timestamp":1790817717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425007823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0923753425007823"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.06.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}